Adjunctive Zoledronate + IL-2 administrations enhance anti-tuberculosis Vγ2Vδ2 T-effector populations, and improve treatment outcome of multidrug-resistant tuberculosis(1)

Multidrug-resistant tuberculosis (MDR-TB) is a refractory disease with high mortality rate due to no or few choices of antibiotics. Adjunctive immunotherapy may help improve treatment outcome of MDR-TB. Our decade-long studies demonstrated that phosphoantigen-specific Vγ2Vδ2 T cells play protective...

Descripción completa

Detalles Bibliográficos
Autores principales: Shen, Hongbo, Yang, Enzhuo, Guo, Ming, Yang, Rui, Huang, Guixian, Peng, Ying, Sha, Wei, Wang, Feifei, Shen, Ling
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2022
Materias:
Tuberculosis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9310823/
https://www.ncbi.nlm.nih.gov/pubmed/35765887
http://dx.doi.org/10.1080/22221751.2022.2095930

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9310823/
https://www.ncbi.nlm.nih.gov/pubmed/35765887
http://dx.doi.org/10.1080/22221751.2022.2095930

Ejemplares similares